Crossref Citations
This article has been cited by the following publications. This list is generated based on data provided by
Crossref.
Morgan, J. F.
1999.
Ecstasy use and neuropathology.
British Journal of Psychiatry,
Vol. 175,
Issue. 6,
p.
589.
Burgess, C.
O’Donohoe, A.
and
Gill, M.
2000.
Agony and ecstasy: a review of MDMA effects and toxicity.
European Psychiatry,
Vol. 15,
Issue. 5,
p.
287.
Gold, Mark S.
and
Tabrah, Haleh
2000.
Update on the Ecstasy Epidemic.
Journal of Addictions Nursing,
Vol. 12,
Issue. 3-4,
p.
133.
Boot, Brandon P
McGregor, Iain S
and
Hall, Wayne
2000.
MDMA (Ecstasy) neurotoxicity: assessing and communicating the risks.
The Lancet,
Vol. 355,
Issue. 9217,
p.
1818.
Irvine, Rodney J.
Toop, Natasha P.
Phillis, Benjamin D.
and
Lewanowitsch, Tanya
2001.
The acute cardiovascular effects of 3,4‐methylenedioxymethamphetamine (MDMA) and p‐methoxyamphetamine (PMA).
Addiction Biology,
Vol. 6,
Issue. 1,
p.
45.
Cottler, Linda B.
Womack, Sharon B.
Compton, Wilson M.
and
Ben‐Abdallah, Arbi
2001.
Ecstasy abuse and dependence among adolescents and young adults: applicability and reliability of DSM‐IV criteria.
Human Psychopharmacology: Clinical and Experimental,
Vol. 16,
Issue. 8,
p.
599.
Teter, Christian J.
and
Guthrie, Sally K.
2001.
A Comprehensive Review of MDMA and GHB: Two Common Club Drugs.
Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy,
Vol. 21,
Issue. 12,
p.
1486.
O’Leary, Grace
Nargiso, Jessica
and
Weiss, Roger D.
2001.
3,4-methylenedioxymethamphetamine (mdma): A review.
Current Psychiatry Reports,
Vol. 3,
Issue. 6,
p.
477.
BUCHERT, R.
OBROCKI, J.
THOMASIUS, R.
VÄTERLEIN, O.
PETERSEN, K.
JENICKE, L.
BOHUSLAVIZKI, K. H.
and
CLAUSEN, M.
2001.
Long-term effects of ‘ecstasy’ abuse on the human brain studied by FDG PET.
Nuclear Medicine Communications,
Vol. 22,
Issue. 8,
p.
889.
Reneman, Liesbeth
Booij, Jan
Majoie, Charles B. L. M.
van den Brink, Wim
and
den Heeten, Gerard J.
2001.
Investigating the potential neurotoxicity of Ecstasy (MDMA): an imaging approach.
Human Psychopharmacology: Clinical and Experimental,
Vol. 16,
Issue. 8,
p.
579.
Tassi, Patricia
and
Muzet, Alain
2001.
Defining the states of consciousness.
Neuroscience & Biobehavioral Reviews,
Vol. 25,
Issue. 2,
p.
175.
Simon, Neil G.
and
Mattick, Richard P.
2002.
The impact of regular ecstasy use on memory function.
Addiction,
Vol. 97,
Issue. 12,
p.
1523.
GOWING, LINDA R.
HENRY‐EDWARDS, SUSAN M.
IRVINE, RODNEY J.
and
ALI, ROBERT L.
2002.
The health effects of ecstasy: a literature review.
Drug and Alcohol Review,
Vol. 21,
Issue. 1,
p.
53.
Hurley, Robin A.
Reneman, Liesbeth
and
Taber, Katherine H.
2002.
Ecstasy in the Brain.
The Journal of Neuropsychiatry and Clinical Neurosciences,
Vol. 14,
Issue. 2,
p.
125.
Freese, Thomas E.
Miotto, Karen
and
Reback, Cathy J.
2002.
The effects and consequences of selected club drugs.
Journal of Substance Abuse Treatment,
Vol. 23,
Issue. 2,
p.
151.
Obrocki, J
Schmoldt, A
Buchert, R
Andresen, B
Petersen, K
and
Thomasius, R
2002.
Specific neurotoxicity of chronic use of ecstasy.
Toxicology Letters,
Vol. 127,
Issue. 1-3,
p.
285.
Montz Andrée, R.
Jiménez Vicioso, A.
Coullaut Jáuregui, J.
López-Ibor Aliño, J.J.
and
Carreras Delgado, J.L.
2002.
PET en neurología y psiquiatría I. PET con FDG en el estudio del SNC.
Revista Española de Medicina Nuclear,
Vol. 21,
Issue. 5,
p.
370.
Baggott, Matthew J.
2002.
Preventing Problems in Ecstasy Users: Reduce Use to Reduce Harm.
Journal of Psychoactive Drugs,
Vol. 34,
Issue. 2,
p.
145.
Ochoa Mangado, Enriqueta
2002.
Drogas de diseño.
Medicina Clínica,
Vol. 119,
Issue. 10,
p.
375.
Bialer, Philip A
2002.
Designer drugs in the general hospital.
Psychiatric Clinics of North America,
Vol. 25,
Issue. 1,
p.
231.
eLetters
No eLetters have been published for this article.